Transgene and NEC Bio Forge Partnership for TG4050 Development

Transgene and NEC Bio B.V., a subsidiary of NEC Corporation, have signed a license agreement to advance TG4050, an individualized neoantigen therapeutic vaccine, in the treatment of resected HPV-negative head and neck cancer. TG4050 employs an MVA viral vector and NEC’s AI-powered prediction platform to prevent relapse and extend disease-free survival post-surgery.

The agreement grants Transgene access to NEC’s neoantigen prediction technology, aiding further clinical development and potential commercialization. NEC retains AI platform ownership but supports continued clinical activities. A combination of cash and Transgene shares will compensate NEC, including milestone payments and profit shares.

This collaboration marks a milestone in the joint venture, with both companies committed to improving head and neck cancer treatment outcomes.